2020 News Releases
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
LOS ANGELES, Calif., Jan. 13, 2020 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a
biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach,
will be presenting at the 38 th Annual J.P. Morgan Healthcare Conference at 12:00 p.m. PST on
Wednesday, January 15, 2020. Mr. Auerbach will be providing a corporate update that will include, among
other things, the companyâ€™s preliminary estimate that it sold approximately 4,900 bottles of NERLYNX in
the United States in the fourth quarter of 2019. This preliminary estimate is subject to completion of the
Companyâ€™s customary closing and review procedures and could change based on that process. The slides to
be discussed during the presentation are currently available on the Investors section of Pumaâ€™s website at
https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx.Â A live webcast of the
presentation will also be available on January 15, 2020, at www.pumabiotechnology.com.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licenses the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended
adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following
adjuvant trastuzumab-based therapy and is marketed in the United States as NERLYNXÂ® (neratinib) tablets.
NERLYNX was granted marketing authorization by the European Commission in August 2018 for the
extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-
overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant
trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
# # # # #
Back to 2020 News Releases
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024